Vivelix licenses first candidate; gets global rights to Idera's IMO9200; Deal terminated
Idera Pharmaceuticals Inc. licensed eight-month-old Vivelix Pharmaceuticals Ltd. exclusive worldwide rights (including rights to sublicense) to develop and market IMO9200 for non-malignant gastrointestinal disorders.
- Antisense, Oligonucleotides
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.